Results 221 to 230 of about 121,575 (281)

Regimen-Specific Population Pharmacokinetics of Isoniazid with and Without Rifamycin: A Bayesian Modeling Analysis of 6H, 3HR, and 3H2P2 Regimens. [PDF]

Pharmaceutics
Li Z, Xiao X, Xu C, Liu Y, Gu L, Li X, Shen X, Hu Y.   +7 more
europepmc   +1 more source

Formal Comment on "Platelet-leucocyte interactions drive MMP-mediated tissue damage in tuberculosis" (Kirwan et al., 2026). [PDF]

PLoS Pathog
Shan Q.
europepmc   +1 more source

Alternative ribosome expression alone is insufficient to drive antibiotic tolerance in <i>Mycobacterium bovis</i> BCG. [PDF]

Front Microbiol
Butler RE, Barber J, Mayson G, Wallis G, Stewart GR.   +4 more
europepmc   +1 more source

Dual-Functional Antibiotic Adjuvants Based on Antibacterial Polyesters With Guanidinium and Boronic Acid Motifs. [PDF]

Macromol Biosci
Qian YL, Li W, Cheng Y, Liu Q, Zhang XT, Du FS, Li ZC.   +6 more
europepmc   +1 more source

Adjunctive rifampicin-ofloxacin therapy in histoid Hansen disease with high bacillary burden: a case report. [PDF]

Skin Health Dis
Nitya VN, Singh A, Madke BS, Kondalkar A, H V.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Rifampicin quinone is an immunosuppressant, but not rifampicin itself

Clinical Immunology and Immunopathology, 1988
Rifampicin as a potential immunosuppressive agent was tested in the rat. A freshly made-up solution of this labile antibiotic in a daily dosage of 20 mg/kg iv did not affect mean graft survival time in a heterotopic heart transplant model. However, when stored solutions of rifampicin were used mean graft survival time was significantly prolonged (from ...
P, Konrad, P, Stenberg
openaire   +2 more sources

RIFAMPICIN

The Lancet, 1969
J M, Murdoch, C F, Speirs, N, Wright, E T, Wallace   +3 more
openaire   +4 more sources

RIFAMPICIN AND THROMBOCYTOPENIA

The Lancet, 1971
R, Esposito, D, Vitali
  +7 more sources